How does retatrutide work?

Retatrutide works by targeting GLP-1, GIP, and glucagon receptors simultaneously to support weight loss, energy expenditure, appetite regulation, and metabolic health improvements.

Retatrutide vs. Ozempic: Weight Loss, Semaglutide, Tirzepatide

Q: Is retatrutide approved by the FDA?

No. Retatrutide is an investigational medication that is still in phase 3 clinical development and has not yet been approved by the FDA.

Q: What are the common side effects of retatrutide and Ozempic?

Common side effects of retatrutide and Ozempic include nausea, vomiting, diarrhea, constipation, abdominal discomfort, and other gastrointestinal side effects often associated with GLP-1 medications.

Reviewed by

Dr. Alexander Voss, PhD

Former Research Associate, European Peptide Institute

Dr. Voss is a peptide research specialist with 10+ years of experience in molecular biology and synthetic peptide analysis, focusing on compound characterization and laboratory-grade purity standards.

Explore Research Peptides

Retatrutide vs Ozempic: Which GLP-1 Weight Loss Medication Performs Better?

Retatrutide vs Ozempic: Comparing GLP-1 Weight Loss Medications

As GLP-1 medications continue transforming obesity and type 2 diabetes treatment, many patients are now comparing retatrutide vs Ozempic to determine which therapy may offer superior weight loss and metabolic health benefits.

Retatrutide, semaglutide, and tirzepatide are among the most discussed weight loss drugs currently being studied or prescribed. While Ozempic and Wegovy are already FDA-approved medications containing semaglutide, retatrutide is an investigational GLP-1 receptor agonist currently undergoing clinical trial evaluation.

Researchers believe retatrutide may produce greater weight loss than medications like Ozempic due to its unique triple receptor agonist mechanism.

What Is Retatrutide?

Retatrutide is an investigational weight loss medication developed by Eli Lilly. Unlike traditional GLP-1 receptor agonist therapies, retatrutide is a triple agonist that targets:

GLP-1 receptor
GIP receptor
Glucagon receptor

This means retatrutide targets multiple hormone pathways involved in appetite regulation, insulin secretion, gastric emptying, blood sugar control, and energy expenditure.

Retatrutide is a triple receptor agonist designed to promote weight loss, improve metabolic health, and support long-term weight management in people with obesity and type 2 diabetes.

What Is Ozempic?

Ozempic is a semaglutide-based GLP-1 receptor agonist approved by the FDA for type 2 diabetes treatment and widely prescribed off-label for weight loss.

Ozempic works by:

Increasing insulin secretion
Slowing gastric emptying
Reducing appetite
Improving blood sugar control

Ozempic and Wegovy both contain semaglutide, although Wegovy is specifically approved for chronic weight management at higher doses.

Among GLP-1 medications like Ozempic, semaglutide remains one of the most widely prescribed options worldwide.

Retatrutide vs Ozempic Mechanism of Action

One of the biggest differences in retatrutide vs Ozempic comparisons is receptor activity.

Retatrutide

Retatrutide is a triple agonist targeting:

GLP-1 receptor
GIP receptor
Glucagon receptor

This combination may enhance:

Fat loss
Energy expenditure
Weight loss effects
Metabolic flexibility

Ozempic

Ozempic is a GLP-1 receptor agonist only.

It primarily supports:

Appetite reduction
Slower gastric emptying
Improved insulin secretion
Better blood sugar management

Because retatrutide and tirzepatide involve additional receptor pathways beyond GLP-1 alone, researchers believe these newer medications may provide superior weight loss efficacy.

Clinical Trial Results for Retatrutide vs Ozempic

Retatrutide Clinical Trial Data

Clinical trial research suggests retatrutide produced substantial weight loss in participants receiving retatrutide during phase 2 trial investigations.

Some studies reported:

Significant body weight reduction
Greater weight loss over 48 weeks
Sustained weight loss during long-term follow-up
Average weight loss exceeding many existing GLP-1 medications

Data for retatrutide also suggest the medication may improve metabolic health and body weight loss outcomes more aggressively than older therapies.

Retatrutide dosing in clinical trials has included escalating higher dose schedules to maximize weight loss benefits while helping minimize gastrointestinal side effects.

Ozempic Clinical Trial Data

Ozempic has demonstrated strong weight loss results across multiple clinical trial programs lasting up to 68 weeks.

Studies involving semaglutide reported:

Significant weight loss
Improved blood sugar control
Better cardiovascular markers
Long-term weight management support

Ozempic users frequently experience meaningful fat loss and improved glycemic control, particularly when combined with lifestyle interventions.

Retatrutide vs Tirzepatide

Tirzepatide and retatrutide are often compared because both medications target GLP-1 and GIP receptors.

However, retatrutide is a triple agonist because it also activates the glucagon receptor.

This additional receptor activity may contribute to:

Greater weight loss
Higher energy expenditure
Maximum weight loss potential
Superior weight loss compared with dual agonist therapies

Researchers continue evaluating retatrutide and tirzepatide in ongoing phase 3 clinical trials.

Weight Loss Results: Which Medication Works Better?

Current trials of retatrutide suggest the medication may deliver superior weight loss compared with semaglutide-based medications like Ozempic.

Weight Loss Compared

Research findings suggest:

Medication	Estimated Weight Loss
Ozempic (Semaglutide)	Significant weight loss over 68 weeks
Tirzepatide	Greater weight loss than semaglutide
Retatrutide	Substantial weight loss and body weight reduction in early trials

Some researchers believe retatrutide may eventually become one of the most effective weight loss injections available.

Side Effects and Safety

Common Side Effects

Like most GLP-1 medications, both retatrutide and Ozempic may cause gastrointestinal side effects.

Common side effect concerns include:

Nausea
Vomiting
Diarrhea
Constipation
Abdominal discomfort

Side Effects and Safety Comparison

Ozempic has established long-term safety data because it is already FDA approved.

Retatrutide is still in phase 3 trials, meaning long-term side effects and safety outcomes are still under investigation.

Researchers are evaluating whether retatrutide works effectively at higher dose levels without causing excessive discontinuation due to side effects.

Is Retatrutide Approved?

Retatrutide is not yet approved by the FDA.

Retatrutide is still in phase 3 clinical development, while Ozempic is already commercially available by prescription.

Additional phase 3 trials for retatrutide are expected to provide more information about:

Long-term safety
Weight loss efficacy
Cardiovascular outcomes
Body weight reduction durability

Which Weight Loss Medication Is Better?

Choosing between retatrutide vs Ozempic depends on:

Weight loss goals
Type 2 diabetes status
Tolerance for side effects
Healthcare provider recommendations
Insurance coverage
Access to prescription medications

For now, Ozempic remains one of the most accessible GLP-1 medications available. However, many experts believe retatrutide may eventually redefine obesity treatment if ongoing phase 3 trial data continue showing substantial weight loss and metabolic benefits.

Frequently Asked Questions

What is the difference between retatrutide and Ozempic?

Retatrutide is a triple receptor agonist targeting GLP-1, GIP, and glucagon receptors, while Ozempic is a semaglutide-based GLP-1 receptor agonist only.